BRPI0510570A - composição de vacina - Google Patents

composição de vacina

Info

Publication number
BRPI0510570A
BRPI0510570A BRPI0510570-6A BRPI0510570A BRPI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A
Authority
BR
Brazil
Prior art keywords
vaccine composition
antigen
vaccine
eso
saponin
Prior art date
Application number
BRPI0510570-6A
Other languages
English (en)
Inventor
Vincent Brichard
Remi M Palmantier
Melinda Meaders
Claudine Elvire Marie Bruck
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0510570A publication Critical patent/BRPI0510570A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO DE VACINA. A presente invenção fornece novas formulações de vacina para o tratamento de antígenos do câncer. A vacina compreende um antígeno MAGE-3 modificado, um antígeno NY-ESO- 1, e um adjuvante compreendendo uma saponina e um oligonucleotídeo imunoestimulador.
BRPI0510570-6A 2004-05-04 2005-05-02 composição de vacina BRPI0510570A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine
PCT/EP2005/004956 WO2005105139A2 (en) 2004-05-04 2005-05-02 Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
BRPI0510570A true BRPI0510570A (pt) 2007-11-20

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510570-6A BRPI0510570A (pt) 2004-05-04 2005-05-02 composição de vacina

Country Status (16)

Country Link
US (1) US20070243196A1 (pt)
EP (1) EP1755657A2 (pt)
JP (1) JP2007536326A (pt)
CN (1) CN1980691A (pt)
AU (1) AU2005237256A1 (pt)
BR (1) BRPI0510570A (pt)
CA (1) CA2564470A1 (pt)
GB (1) GB0409940D0 (pt)
IL (1) IL178681A0 (pt)
MA (1) MA28639B1 (pt)
MX (1) MXPA06012723A (pt)
NO (1) NO20065480L (pt)
NZ (1) NZ550967A (pt)
RU (1) RU2006138283A (pt)
WO (1) WO2005105139A2 (pt)
ZA (1) ZA200608693B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186049A1 (en) * 2006-05-26 2009-07-23 Vincent Brichard Method of treating mage positive cancer
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
EP2118128B1 (en) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
PL2457928T3 (pl) 2007-03-13 2017-10-31 Univ Zuerich Monoklonalne ludzkie przeciwciało swoiste względem nowotworu
CN101678091A (zh) * 2007-05-24 2010-03-24 葛兰素史密丝克莱恩生物有限公司 冷冻干燥的抗原组合物
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20130295091A1 (en) * 2011-01-10 2013-11-07 University Of Zurich Combination therapy including tumor associated antigen binding antibodies
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016019298A2 (en) * 2014-08-01 2016-02-04 Texas Tech University System Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US11945851B2 (en) 2017-06-07 2024-04-02 The Wistar Institute Of Anatomy And Biology MAGE-A vaccines and methods of treatment using the same
WO2019061297A1 (zh) 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
AU725615B2 (en) * 1996-02-23 2000-10-12 British Telecommunications Public Limited Company Optical interconnect
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
ZA200608693B (en) 2010-01-27
JP2007536326A (ja) 2007-12-13
MA28639B1 (fr) 2007-06-01
US20070243196A1 (en) 2007-10-18
MXPA06012723A (es) 2007-02-14
IL178681A0 (en) 2007-02-11
RU2006138283A (ru) 2008-06-10
CN1980691A (zh) 2007-06-13
NO20065480L (no) 2006-11-28
EP1755657A2 (en) 2007-02-28
CA2564470A1 (en) 2005-11-10
GB0409940D0 (en) 2004-06-09
NZ550967A (en) 2009-01-31
AU2005237256A1 (en) 2005-11-10
WO2005105139A3 (en) 2006-04-13
WO2005105139A2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
NO20065480L (no) Vaksiner.
CY1116108T1 (el) Εμβολιο ιου ερπητα ζωστηρα
EP2228072A4 (en) CANCER VACCINE COMPOSITION
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
CY1116904T1 (el) Εμβολιο
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
TW200722101A (en) Novel composition
MX375202B (es) Composiciones adyuvantes novedosas.
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
CL2019002876A1 (es) Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes.
ATE426412T1 (de) Adjuvante influenza-vakzine
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral
MX2010003415A (es) Proceso ex vivo, rápido y eficiente para la obtención de células presentadoras de antígenos activadas, útiles para las terapias contra el cáncer y enfermedades relacionadas con el sistema inmunológico.
EA201001478A1 (ru) Вакцина
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
TNSN07187A1 (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. their use in the treatment of cancer
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
GB2444676A (en) Adjuvanted vaccine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.